Abstract | BACKGROUND: METHODS: The primary study end-point was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Hypertension was defined according to medical history and current blood pressure values at entry and could be determined in 682 of 716 patients of the intention-to-treat analysis. RESULTS: One hundred and fifty-seven patients (23%) were normotensives and 525 (77%) hypertensives. In the normotensive population the primary end-point occurred in 19 of 76 zofenopril-treated patients (25%) and in 23 of 81 ramipril-treated patients (28%) [odds ratio (95% confidence interval): 0.84 (0.41-1.71), P = 0.631]. In the hypertensive population, major cardiovascular outcomes were reported in 84 of 273 zofenopril-treated patients (31%) and in 99 of 252 ramipril-treated patients (39%), with a 31% significantly (P = 0.041) lower risk with zofenopril [0.69 (0.48-0.99)]. The superiority of zofenopril versus ramipril was particularly evident in patients with isolated systolic hypertension [n = 131, 0.48 (0.23-0.99), P = 0.045]. CONCLUSION: This retrospective analysis of the SMILE-4 study confirmed the good efficacy of zofenopril and ASA in the prevention of long-term cardiovascular outcomes also in the subgroup of patients with hypertension.
|
Authors | Claudio Borghi, Ettore Ambrosioni, Stefano Omboni, Arrigo F G Cicero, Stefano Bacchelli, Daniela D Esposti, Dragos Vinereanu, Giuseppe Ambrosio, Dario Zava, SMILE-4 Working Party |
Journal | Journal of hypertension
(J Hypertens)
Vol. 31
Issue 6
Pg. 1256-64
(Jun 2013)
ISSN: 1473-5598 [Electronic] England |
PMID | 23552127
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antihypertensive Agents
- Platelet Aggregation Inhibitors
- zofenopril
- Captopril
- Ramipril
- Aspirin
|
Topics |
- Aged
- Antihypertensive Agents
(pharmacology, therapeutic use)
- Aspirin
(pharmacology, therapeutic use)
- Blood Pressure
(drug effects)
- Captopril
(analogs & derivatives, pharmacology, therapeutic use)
- Europe
(epidemiology)
- Female
- Humans
- Hypertension
(complications, drug therapy, mortality)
- Male
- Middle Aged
- Myocardial Infarction
(prevention & control)
- Platelet Aggregation Inhibitors
(pharmacology, therapeutic use)
- Ramipril
(pharmacology, therapeutic use)
- Randomized Controlled Trials as Topic
- Retrospective Studies
- Ventricular Dysfunction, Left
(complications, drug therapy, mortality)
|